The FDA approved Revolution Medicines' daraxonrasib on August 26–27, 2026, a landmark pancreatic cancer treatment that nearly doubled average survival times in trials; the drug is priced above $475,000 annually.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
FDA approves landmark pancreatic cancer drug that’s shown to improve survival AP News
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.
this outlet adds: blocking, protein, fuels, tumor, growth, vast, majority, cases
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer The US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease. FDA officials gave expedited approval to the first-of-a-kind pill, c
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque. It was approved for patients who already tried...
The Food and Drug Administration on Wednesday approved a groundbreaking pancreatic cancer drug that experts predict will transform treatment for the notoriously deadly disease.
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.
The FDA has approved a drug that could extend the life of patients with late-stage pancreatic cancer. CBS News' medical correspondent Dr. Céline Gounder has more.
“We’ve never seen a benefit like this,” said Anna Berkenblit, the chief scientific and medical officer at the Pancreatic Cancer Action Network.
Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wedn